Introduction
Eko Health is a medical technology company founded in 2013 in Emeryville, California, by Connor Landgraf. It builds digital stethoscopes that capture high-fidelity heart and lung sounds and pairs them with AI algorithms designed to detect cardiac abnormalities during routine physical exams. Where hospital cardiology AI often depends on CT, MRI, or echocardiography infrastructure, Eko’s model attaches AI to a tool primary care physicians already use — the stethoscope — potentially expanding screening reach to settings without advanced imaging.
Eko’s SENSORA platform includes EFAST, an FDA-cleared algorithm for low ejection fraction detection, and received a CMS CPT code effective July 1, 2025. Those regulatory and reimbursement milestones are verified through Eko’s official newsroom and anchor this profile.
Primary care is where many heart failure and valvular disease cases are first suspected; tools that extend screening without echocardiography on every patient address a practical access gap rather than a research-only use case.
Connor Landgraf’s founding vision centered on digitizing one of the last common analog clinical instruments — the stethoscope — rather than building yet another hospital-only imaging pipeline.
What the company does
Eko manufactures FDA-cleared digital stethoscope hardware — including CORE and DUO product lines — that stream audio to mobile and cloud software. Its SENSORA AI platform analyzes phonocardiogram and ECG data to flag murmurs, atrial fibrillation, and low ejection fraction suggestive of heart failure. EFAST specifically targets low-EF detection during a standard stethoscope exam, aiming to identify patients who need echocardiography follow-up before symptoms escalate. Eko sells device-plus-software subscriptions rather than pure software licenses.
Who it serves
Eko serves primary care and internal medicine practices, cardiology clinics, urgent care settings, and telehealth programs that need cardiac screening without immediate echocardiography access. Health systems deploying Eko often target heart failure detection in underserved populations and rural clinics where specialist imaging backlog delays diagnosis. The July 2025 CMS CPT code for SENSORA matters to these buyers because it creates a billing pathway for AI-assisted stethoscope exams in fee-for-service environments.
Connor Landgraf’s founding focus on the stethoscope as an underdigitized clinical tool distinguishes Eko from imaging-first cardiology AI vendors in the same sector coverage.
Company background
Connor Landgraf co-founded Eko in 2013 in Emeryville, developing digital stethoscope prototypes that improved audio capture and connectivity compared with traditional acoustic instruments. The company progressed through FDA clearance pathways for both hardware and software components — a longer road than pure SaaS clinical AI but one that creates durable regulatory moats. Eko rebranded from “Eko” to “Eko Health” in its public-facing materials while maintaining focus on cardiovascular and pulmonary AI detection at the point of care.
Emeryville’s location in the San Francisco Bay Area medical device corridor placed Eko near audiology and cardiac hardware suppliers, reflecting the company’s blended device-and-software identity rather than a cloud-only AI startup profile.
Product and AI capabilities
Eko’s AI models analyze heart sound patterns and associated ECG signals to classify murmurs and rhythm abnormalities, with EFAST extending detection to low ejection fraction — a condition traditionally requiring echocardiography. FDA clearance for EFAST, documented in Eko’s newsroom, indicates the algorithm met agency thresholds for clinical decision support in this indication. SENSORA’s CMS CPT code, effective July 1, 2025 per Eko’s announcement, represents a reimbursement milestone that can accelerate adoption among practices that otherwise hesitate to deploy uncoded AI tools.
Key developments
2013: Eko Health founded in Emeryville by Connor Landgraf. FDA clearance: EFAST low ejection fraction algorithm cleared under SENSORA (Eko newsroom). July 1, 2025: CMS CPT code for SENSORA effective (Eko newsroom).
EFAST clearance and the July 2025 CPT effective date together address the two gates that most often slow clinical AI adoption in primary care: regulatory clearance for the algorithm and a billing code for the service.
Both milestones are documented on Eko Health’s official newsroom pages cited below.
Why it matters
Eko Health matters because most heart failure and valvular disease is first encountered in primary care, not in catheterization labs — and because AI that works on a stethoscope could shift screening earlier in the disease course if clinicians trust the algorithms and payers reimburse them. EFAST FDA clearance and the July 2025 CPT code are the kind of verifiable milestones that separate regulated medical AI from wellness-device noise. Eko also complements CT-based cardiology AI from HeartFlow and Cleerly: Eko screens at the bedside; those companies analyze imaging for patients already in advanced diagnostic pathways.
The July 2025 CPT effective date gives Eko a billing anchor in fee-for-service environments where uncoded AI tools struggle to justify line-item charges on claims.
Sector context
Eko Health sits in Brel’s AI in healthcare coverage under cardiology and point-of-care diagnostics, distinct from imaging-heavy vendors and from ambient documentation tools such as Suki AI. Readers comparing form factors should note Eko’s hardware dependency versus pure software cardiovascular AI — different capital, regulatory, and deployment economics.
Sources and references
Eko Health newsroom posts on EFAST FDA clearance and SENSORA CPT code (July 1, 2025).
- Eko Health — EFAST FDA clearance (ekohealth.com newsroom)
- Eko Health — SENSORA CPT code effective July 1, 2025 (ekohealth.com newsroom)
Reviewed July 10, 2026. Connor Landgraf is founder.